---
title: Role of Oxytocin in Myocardial Infarction
nct_id: NCT03001635
overall_status: UNKNOWN
phase: PHASE2, PHASE3
sponsor: Sheba Medical Center
study_type: INTERVENTIONAL
primary_condition: Myocardial Infarction
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03001635.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03001635"
ct_last_update_post_date: 2016-12-23
last_seen_at: "2026-05-12T06:47:30.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Role of Oxytocin in Myocardial Infarction

**Official Title:** The Impact of Oxytocin Administration on Short and Long Term Prognosis in Patients Undergoing ST Elevation Myocardial Infarction

**NCT ID:** [NCT03001635](https://clinicaltrials.gov/study/NCT03001635)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE2, PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 52
- **Lead Sponsor:** Sheba Medical Center
- **Conditions:** Myocardial Infarction
- **Start Date:** 2017-01
- **CT.gov Last Update:** 2016-12-23

## Brief Summary

60 patients admitted to this ICCU at the Sheba medical Center will be randomly divided in to 2 groups. one group will receive the conventional treatment while the second group will receive the conventional treatment plus oxytocin infusion for 48 hours. all participants will undergo echo and cMRI during hospitalization.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* age \> 18 years
* current diagnosis of ST elevation myocardial infarction
* no previous episodes of acute coronary syndrome
* agreed to enter research

Exclusion Criteria:

* age \< 18 years
* congestive heart failure (acute or chronic)
* cardiomyopathy
* life threatening arrhythmia at presentation
* previous LV dysfunction
* hypotension (systolic \< 100mmHg, diastolic\<50mmHg, 15% less than patients normal values)
* tachycardia - pulse \> 100bpm
* bradycardia - pulse \< 55 ppm
* killip 3 or 4 at presentation
* current use of nitrates
* pregnancy
* females - history of pathological GU bleeding
* inability to give consent
```

## Arms

- **conventional treatment and oxytocin** (EXPERIMENTAL) — 26 patients admitted to the ICCU under a diagnosis of STEMI will receive treatment with oxytocin as an add on to the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers \& ACE inhibitors). At admission, a continuance infusion with oxytocin will be initiated for a time period of 6 hours. 10 units of oxytocin will be diluted in 1 liter of 0.9% normal saline. the infusion will start at a rate of 2.5 milliunits/min. dosage will be increased at a rate of 5 milliuinits/min every 30 min if there are no side effect, up to a maximum dosage of 30 milliunits/min.
- **conventional treatment only** (PLACEBO_COMPARATOR) — 26 patients admitted to the ICCU under a diagnosis of STEMI will receive the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers \& ACE inhibitors). On admission, an infusion of 0.9 normal saline will be stared as placebo.

## Interventions

- **Oxytocin** (DRUG) — 26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
- **Placebos** (DRUG) — 26 patients will receive 0.9% normal saline infusion for 6h as placebo

## Primary Outcomes

- **final infarction size** _(time frame: 1 week)_ — all patients will undergo an cMRI after 7 days

## Secondary Outcomes

- **Ejection fraction** _(time frame: 48 hours)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03001635.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03001635*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*